Congressional subcommittee criticizes NIH for lax conflict of interest policies. NIH Director Zerhouni promises change. The subcommittee has asked several NCI officials to testify at another hearing next week.
Also in this 8-page issue: Intel Chairman Andrew Grove slams NCI director and cancer program for “wishful dreams” and “chemo speeches,” recommends moratorium on funding for cancer research.
Trending Stories
- On Day 2 as director of NYU Perlmutter, Anirban Maitra talks about the advantages of running a matrix cancer center
- Spending bill passed by the House gives NIH $415M raise, NCI gets $128M
Legislation caps proportion of NIH grants to receive multiyear funding; indirect costs remain untouched - Letai: NCAB’s ad hoc working group plays major role in advising NCI on extramural research
The group replaced the NCI Board of Scientific Advisors - Supportive cancer care is the smart investment our leaders in Washington can’t afford to ignore
- Mail-out colorectal cancer screening programs extend, rather than replace, clinical care
- After a brief government shutdown, FY26 funding bill is signed into law
NIH gets $415M raise, NCI gets $128M more, CDMRP funding largely restored









